Kilitch Drugs (India) Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.
KILITCH · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 7.8 pts more than Nifty Microcap 250 and 7.7 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Kilitch Drugs reported strong FY25 results with standalone net sales rising ~38% to Rs. 18,158.73 lakhs (FY24: Rs. 13,159.90 lakhs) and net profit after tax jumping ~77% to Rs. 3,115.69 lakhs (FY24: Rs. 1,757.38 lakhs), lifting EPS to Rs. 19.37 from Rs. 11.03. On a consolidated basis, revenue grew ~28% to Rs. 19,831.85 lakhs and PAT nearly doubled to Rs. 2,494.01 lakhs. The statutory auditor C. Sharat & Associates issued an unqualified (unmodified) opinion on both standalone and consolidated results. The company significantly expanded its capital base, with capital work-in-progress rising sharply to Rs. 1,729.45 lakhs (from Rs. 596.50 lakhs) and new long-term borrowings of Rs. 2,777.04 lakhs, indicating major capex underway. Operating cash flow improved substantially to Rs. 1,523.28 lakhs (standalone) from a negative Rs. 258.16 lakhs in FY24.
Strong top-line and bottom-line growth with margin expansion is positive for shareholders. However, the sharp increase in borrowings and a large capital work-in-progress balance signal heavy ongoing investment, which could pressure short-term cash flows but supports future capacity. Overall, the results are constructive for the stock given robust earnings growth and a clean audit opinion.